ROVI CDMO Business Unit rebrands and acquires a US injectable manufacturing facility to strengthen global capacity
[Madrid, Spain – September 29, 2025] – ROVI CDMO Business Unit today announces its rebrand to ROIS and the acquisition of a commercial injectable manufacturing and packaging facility in Phoenix, Arizona (USA). The move marks a key step in ROIS’s evolution into a global Contract Development and Manufacturing Organisation (CDMO), adding US-based sterile fill-finish capability while building on its strong European base.
The Phoenix site strengthens ROIS’s ability to develop and manufacture injectable medicines at commercial scale, enhancing capacity, flexibility and speed for pharmaceutical and biotech partners.
“This is a pivotal moment for us,” said Javier López-Belmonte, Vice Chairman of the Board & Chief Financial Officer “Our rebrand and US expansion position ROIS to better support customers worldwide.”
ROIS has built its reputation as a trusted partner in injectable drug development and manufacturing, with end-to-end capabilities spanning early-stage development through to large-scale commercial supply. The company continues to invest in facilities, equipment, and talent to meet growing demand and ensure long-term capacity for its partners worldwide.
With the new brand and expanded global footprint, ROIS is reinforcing its commitment to innovation, quality, and growth — positioning itself as the partner of choice for injectable medicines.
For more information, visit www.roiscdmo.com.
About ROIS
ROIS CDMO is one of the top three CDMOs for injectables worldwide, ROIS is trusted by over 30 global pharma clients to deliver compliant, high-capacity manufacturing with precision and speed. With approvals from leading regulators — including the FDA, EMA, PMDA, KFDA, ANVISA, and MHRA — we offer end-to-end support across formats. Each of our sites is equipped with a dedicated NPI team, ensuring seamless tech transfer and rapid scale-up.
